Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01074320 · ClinicalTrials.gov registry record
Measuring Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors
A clinical trial, sponsored by HealthPartners Institute.
- Completed
- Registry status
- 150
- Enrollment target
NCT01074320: Completed study, sponsored by HealthPartners Institute.
NCT01074320 is a clinical trial that has completed, run by HealthPartners Institute. The registered enrollment target is 150 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01074320 has completed, sponsored by HealthPartners Institute.
- COMPLETED
- Registry status
- 150 participants
- Enrollment target
Study Summary
Current guidelines recommend endocrine treatment with aromatase inhibitors (AIs) in post-menopausal women with hormone receptor-positive breast cancer. Musculoskeletal symptoms are commonly reported with AI treatment,however, we do not have consistent methods to measure these symptoms prospectively. This gap in our knowledge inhibits the ability to test and develop treatments for AI-associated musculoskeletal symptoms. This pilot study will evaluate functional tests and standardized instruments for their ability to prospectively assess musculoskeletal symptoms in women being treated with AIs for breast cancer.
Interventions
- OTHER Other
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2010-02 |
| Est. Completion | 2015-08 |
What the finished NCT01074320 record still lists
NCT01074320 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Other is the first listed.
NCT01074320 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01074320 about?
NCT01074320 is a clinical study titled "Measuring Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors". Current guidelines recommend endocrine treatment with aromatase inhibitors (AIs) in post-menopausal women with hormone receptor-positive breast cancer. Musculoskeletal symptoms are commonly reported with AI treatment,however, we do not have consistent methods to measure these symptoms prospectively....
What is the current status of trial NCT01074320?
This trial is currently completed. The enrollment target is 150 participants. The study started on 2010-02. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01074320?
The interventions under investigation include: Other (OTHER).
Who is sponsoring clinical trial NCT01074320?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia